- Trials with a EudraCT protocol (235)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
235 result(s) found for: Alzheimers Disease AND Senile Dementia, Alzheimer Type AND Dementia.
Displaying page 6 of 12.
EudraCT Number: 2007-002256-42 | Sponsor Protocol Number: 311741 | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:Bayer Schering Pharma AG | |||||||||||||
Full Title: An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/excl... | |||||||||||||
Medical condition: Probable Alzheimer Disease patients compared to Healthy Volunteers. The clinical diagnosis - in Part A made by the investigator, in Part B established by an independent consensus panel of experts... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003109-32 | Sponsor Protocol Number: 1 | Start Date*: 2017-11-23 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: An investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a proof of concept study | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005218-13 | Sponsor Protocol Number: 2167SR | Start Date*: 2012-04-23 | ||||||||||||||||
Sponsor Name:Kings College London [...] | ||||||||||||||||||
Full Title: Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET | ||||||||||||||||||
Medical condition: Alzheimer's Disease and schizophrenia like illness | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001598-25 | Sponsor Protocol Number: IG1002 | Start Date*: 2011-10-25 | |||||||||||
Sponsor Name:INSTITUTO GRIFOLS, S.A. | |||||||||||||
Full Title: A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intra... | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006337-27 | Sponsor Protocol Number: 03140-203 | Start Date*: 2009-03-24 | |||||||||||
Sponsor Name:EPIX Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRX-03140 AS MONOTHERAPY IN SUBJECTS WITH ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005217-37 | Sponsor Protocol Number: I4O-MC-BACC(b) | Start Date*: 2012-08-22 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease | |||||||||||||
Medical condition: Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001478-28 | Sponsor Protocol Number: 3098B1-204-EU | Start Date*: 2007-02-28 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN (SRA-333) SR IN PATIENTS WITH MILD TO MODER... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005089-34 | Sponsor Protocol Number: BRL-049653/461 | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) on cerebral glucose utilisation and cognition in subjects... | |||||||||||||
Medical condition: Alzheimers Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003552-36 | Sponsor Protocol Number: COG0202 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Cognition Therapeutics, Inc. | |||||||||||||
Full Title: A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease | |||||||||||||
Medical condition: Mild to Moderate Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005929-11 | Sponsor Protocol Number: CN156013 | Start Date*: 2009-02-20 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Mode... | |||||||||||||
Medical condition: ALZHEIMER DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003302-27 | Sponsor Protocol Number: ANAVEX2-73-AD-004 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD). | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012179-82 | Sponsor Protocol Number: B0401005 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020427-43 | Sponsor Protocol Number: B0401011 | Start Date*: 2010-10-13 | |||||||||||
Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013689-18 | Sponsor Protocol Number: GALALZ4041 | Start Date*: 2010-05-11 | |||||||||||
Sponsor Name:Janssen-Cilag S.A. | |||||||||||||
Full Title: ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA | |||||||||||||
Medical condition: Enfermedad de Alzheimer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004849-40 | Sponsor Protocol Number: M11-793 | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inh... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000827-25 | Sponsor Protocol Number: AZ3110866 | Start Date*: 2009-01-15 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: Study AZ3110866, a fixed dose study of SB-742457 versus placebo when added to existing donepezil treatment in subjects with mild-to-moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006257-40 | Sponsor Protocol Number: ACI-24-0701 | Start Date*: 2009-12-09 | |||||||||||
Sponsor Name:AC Immune SA | |||||||||||||
Full Title: A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Dis... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011172-30 | Sponsor Protocol Number: A9951007 | Start Date*: 2009-08-10 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S... | |||||||||||||
Medical condition: Mild to Moderate Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005549-39 | Sponsor Protocol Number: EHT 0202/002 | Start Date*: 2007-12-19 | |||||||||||
Sponsor Name:EXONHIT | |||||||||||||
Full Title: A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg ... | |||||||||||||
Medical condition: Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003973-16 | Sponsor Protocol Number: CCAD106A2201 | Start Date*: 2008-06-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated sub... | |||||||||||||
Medical condition: Mild Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) DE (Prematurely Ended) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
